tislelizumab + rituximab + lenalidomide + ifosfamide + carboplatin + etoposide

TR2-ICE is an investigational chemoimmunotherapy combination regimen being evaluated for the treatment of aggressive B-cell lymphomas. The regimen consists of **tislelizumab**, a humanized IgG4 monoclonal antibody that inhibits the Programmed Cell Death Protein 1 (PD-1) checkpoint; **rituximab**, a chimeric monoclonal antibody targeting the CD20 antigen on B-cells; **lenalidomide**, an immunomodulatory drug (IMiD) that targets the cereblon E3 ubiquitin ligase complex; and the **ICE** chemotherapy backbone, which includes **ifosfamide** (an alkylating agent), **carboplatin** (a platinum-based DNA cross-linker), and **etoposide** (a topoisomerase II inhibitor). This combination approach aims to enhance the anti-tumor immune response through checkpoint inhibition and immunomodulation while simultaneously utilizing traditional cytotoxic chemotherapy and targeted monoclonal antibody therapy to overcome resistance in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).

Other names

Tirelizumab combined with R2-ICE regimen